Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck

Table 2 Genotype distribution of the FAS and FASL polymorphisms among patients with index OPC and non-OPC and their associations with risk of SPM

Variables	OPC (N = 42)		Non-OPC (N = 82)		cHRs^a (95 % CI), P		Adj. HRs (95 % CI) ^b, P
	SPM (N)	%	SPM (N)	%	OPC	Non-OPC	OPC	Non-OPC
FAS 670 A > G
AA (ref.)	7	16.7	13	15.9	1.0	1.0	1.0	1.0
AG + GG	35	83.3	69	84.1	1.9 (0.8–4.9), 0.121	2.2 (1.2–5.7), 0.048	2.2 (0.9–5.3), 0.051	2.4 (1.1–5.1), 0.043
FAS 1377 G > A
GG (ref.)	34	80.9	64	78.0	1.0	1.0	1.0	1.0
AG + AA	8	19.1	18	22.0	0.7 (0.3–2.1), 0.435	1.1 (0.4–1.6), 0.378	0.8 (0.4–1.9), 0.476	1.0 (0.5–1.8), 0.622
FASL124 A > G
AA (ref.)	31	73.8	63	76.8	1.0	1.0	1.0	1.0
AG + GG	11	26.2	19	23.2	1.0 (0.4–2.7), 0.489	1.4 (0.7–2.8), 0.567	1.1 (0.5–2.4), 0.587	1.6 (0.9–3.0), 0.124
FASL844 C > T
CC (ref.)	11	26.2	26	31.7	1.0	1.0	1.0	1.0
CT + TT	31	73.8	56	68.3	2.5 (1.1–5.8), 0.043	1.8 (1.1–3.2), 0.041	2.7 (1.2–6.0), 0.032	1.7 (1.0–3.0), 0.049

ref.: reference group
^aCrude HRs
^bHRs were adjusted for age, sex, ethnicity, smoking, alcohol, index cancer stage, and treatment

ISSN: 1471-2407